Target intelligence / Profile preview

Period circadian regulator 3 (PER3)

Target
PER3
Molecular classification
Transcription factor, Clock gene, Other
01

Overview

Period circadian regulator 3 (PER3) is a transcription factor and clock gene that encodes a protein component of the mammalian circadian timing system[1][3][5]. PER3 is structurally related to PER1 and PER2 and is expressed rhythmically in the suprachiasmatic nucleus and peripheral tissues[1][3]. While not essential for maintaining basic circadian rhythms—unlike PER1 and PER2—it contributes to sleep-wake timing, sleep homeostasis, and the regulation of physiological rhythms such as metabolism and behavior[1][3][5]. Polymorphisms in PER3 (notably a variable-number tandem repeat in exon 18) are associated with individual differences in sleep phase preference, vulnerability to sleep deprivation, and diseases including delayed sleep phase syndrome, advanced sleep phase syndrome, type 2 diabetes mellitus, severe obesity, and some neuropsychiatric disorders[3][4][5]. Functionally, PER3 has also been shown to regulate cell fate decisions, particularly inhibiting adipogenesis in mesenchymal stem cells, potentially linking circadian regulation to metabolic outcomes[2][3]. Despite its role in the molecular feedback loops that establish circadian rhythms, PER3's influence is less pronounced than its paralogs PER1 and PER2, and its unique contributions may involve both circadian and non-circadian regulatory pathways[4][6]. There are currently no known drugs specifically targeting PER3, and it is not considered a direct therapeutic target, but its genetic variants may serve as biomarkers for sleep and metabolic disorders[3][5].

Other names
Period circadian protein homolog 3GIG13hPER3Cell growth-inhibiting gene 13 proteinCircadian clock protein PERIOD 3FASPS3period circadian clock 3period circadian protein 3
02

Biological functions

Circadian rhythm regulationSleep-wake timingSleep homeostasisCell fate regulation (adipogenesis)Regulation of metabolismRegulation of behaviorCognitive functionOther
03

Disease associations

Sleep disorders (Delayed sleep phase syndrome, Familial advanced sleep phase syndrome)Type 2 diabetes mellitusObesityBipolar disorderSeasonal affective disorderCognitive impairment/Alzheimer’s diseaseOther
04

Biomarkers

PER3 length polymorphism (VNTR in exon 18)PER3-P415A/H417R polymorphismSNP rs57875989SNP rs228697SNP rs228729

Beyond the preview

Go deeper on Period circadian regulator 3 (PER3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Period circadian regulator 3 (PER3).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call